Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RANEXA Clear all
Withdrawn No phase listed Observational

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

NCT03257683
View directory record Official record
Conditions
Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

NCT03472950
View directory record Official record
Conditions
ALS
Interventions
Ranolazine 500 MG, Ranolazine 1000 MG
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

NCT01917136
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 4 Interventional

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

NCT02156336
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine in Ischemic Cardiomyopathy

NCT01345188
View directory record Official record
Conditions
Cardiomyopathy, Chest Pain, Dyspnea
Interventions
Ranexa, Placebo
Drug
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 4 Interventional Results available

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

NCT00832572
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Houma, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973
View directory record Official record
Conditions
Severe Renal Impairment
Interventions
RANEXA
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 3, 2026, 5:11 PM EDT
Not listed Phase 4 Interventional

Safety of Amiodarone and Ranolazine Together in Patients With Angina

NCT01558830
View directory record Official record
Conditions
Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions
ranolazine, placebo
Drug
Lead sponsor
Cardiovascular Consultants of Nevada
Other
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Henderson, Nevada • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

NCT02251457
View directory record Official record
Conditions
Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
Interventions
Ranolazine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine Implantable Cardioverter-Defibrillator Trial

NCT01215253
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions
Ranolazine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Not applicable Interventional

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756
View directory record Official record
Conditions
Ranolazine, Diastolic Heart Failure, Tissue Doppler Ultrasound, Echocardiography
Interventions
ranolazine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Not applicable Interventional

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

NCT01480336
View directory record Official record
Conditions
Arrhythmia
Interventions
Amiodarone Plus Ranolazine, Amiodarone with Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD

NCT01754259
View directory record Official record
Conditions
Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041
View directory record Official record
Conditions
Atherosclerotic Coronary Vascular Disease
Interventions
Ranolazine 500 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 3, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

Ranolazine Cardioprotection in PCI

NCT01767987
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Harvey Hahn
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 3, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 3, 2026, 5:11 PM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

NCT01979965
View directory record Official record
Conditions
Ischemic Mitral Regurgitation
Interventions
Ranolazine (Active drug), Placebo
Drug
Lead sponsor
University Cardiology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 3, 2026, 5:11 PM EDT